A Clinical Study of TQH2929 in Healthy Adult Subjects - Trial NCT06156280
Access comprehensive clinical trial information for NCT06156280 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 78 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 1
Nov 21, 2023
Apr 01, 2025
Primary Outcome
Adverse events (AE) rate,Serious adverse events (SAE) rate,Treatment-related adverse events (TRAE) rate,Clinical laboratory abnormalities
Summary
This project is divided into a single dose escalation and a multiple dose escalation phase Ia
 clinical study. This is a single-center, randomized, double-blind, placebo-controlled study
 to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929
 injection in healthy adults.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06156280
Non-Device Trial